Navigation Links
Micromet Added to Russell 3000 Index
Date:6/29/2009

Nycomed. Micromet's licensee Morphotek, a wholly-owned subsidiary of Eisai, is also expected to initiate a first phase 1 clinical trial with Micromet's glycolipid-binding human antibody MT228 for the treatment of melanoma.

Micromet's preclinical product pipeline includes several novel BiTE antibodies generated with its proprietary BiTE antibody platform technology. A BiTE antibody targeting CEA for the treatment of solid tumors is being developed in collaboration with MedImmune. In addition, Micromet has entered into an option, collaboration and license agreement with Bayer Schering Pharma AG under which Bayer Schering Pharma was granted an exclusive option to license a specified BiTE antibody against an undisclosed solid tumor target. Other BiTE antibodies targeting MSCP, CD33, HER2, EGFR and other targets are in various stages of preclinical development.

Forward-Looking Statements

This release contains certain forward-looking statements that involve risks and uncertainties that could cause actual results to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. These forward-looking statements include statements regarding the efficacy, safety and intended utilization of our product candidates, the conduct, timing and results of future clinical trials, and expectations of the future expansion of our product pipeline and collaborations. You are urged to consider statements that include the words "ongoing," "may," "will," "believes," "potential," "expects," "plans," "anticipates," "intends," or the negative of those words or other similar words to be uncertain and forward-looking. Factors that may cause actual results to differ materially from any future results expressed or implied by any forward-looking statements include the risk that product candidates that appeared promising in early research, preclinical studies or clinical trials do n
'/>"/>

SOURCE Micromet, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Micromet to Host Conference Call and Webcast to Discuss Blinatumomab Data Presented at EHA on June 8, 2009
2. Micromet Presents Update at ASCO 2009 on a Phase 1b Combination Study of Adecatumumab and Docetaxel
3. Micromet to Present New Clinical Data on Blinatumomab at EHA and on Adecatumumab at ASCO
4. Micromet, Inc. to Host Conference Call and Webcast to Report First Quarter 2009 Financial Results on May 6, 2009
5. Micromet Presents Data at AACR Meeting Showing Elimination of Colorectal Cancer Stem Cells by BiTE Antibody MT110
6. Micromet to Present at the Future Leaders in the Biotech Industry Conference on April 2, 2009
7. Micromet Adds Sir Walter Bodmer and Bernard Fox to Its Advisory Panel for BiTE Antibody Therapeutics
8. Micromet to Present Six Posters on Progress of BiTE Antibodies at the Annual Meeting of American Association for Cancer Research
9. Micromet, Inc. To Regain Rights to Blinatumomab in North America; Reports Financial Results for the Fourth Quarter and Full Year ended December 31, 2008
10. Micromet to Present at the Cowen Health Care Conference on March 17, 2009
11. Micromet Adds Former Head of Roche Oncology Kapil Dhingra, MD to Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/25/2014)... and NEW YORK , ... (OTCQB: ACCPD), formerly Access Pharmaceuticals, Inc. (ACCP), a ... announced it has implemented a 1-for-50 reverse split ... of trading on Friday, October 24, 2014. PlasmaTech,s ... under new CUSIP number 72754H109 and temporary ticker ...
(Date:10/25/2014)... , October 24, 2014 ... http://www.researchandmarkets.com/research/t5t5pd/the_global_market ) has announced the addition of ... Graphene And Other 2-D Nanomaterials "  report ... http://photos.prnewswire.com/prnh/20130307/600769) , ,CNTs and graphene are the ... to man, with a performance-per-weight greater than ...
(Date:10/22/2014)... 21, 2014 The Americas Inorganic ... refrigerants market in Americas with analysis and forecast ... the Americas Inorganic Refrigerants Market report, to get ... also provides a glimpse of the segmentation in ... by various tables and figures. , ...
(Date:10/22/2014)... WriteResult, LLC – a premier ... working with a team of researchers from Yale University’s ... Farming Collaborative to provide electronic questionnaire data collection through ... which started in May, aims to evaluate the impact ... exposure to and participation in urban agriculture to impact ...
Breaking Biology Technology:PlasmaTech Biopharmaceuticals, Inc. Announces Reverse Stock Split, Ticker Change and Launches New Corporate Website 2The Global Market for Carbon Nanotubes, Graphene and Other 2-D Nanomaterials 2The Global Market for Carbon Nanotubes, Graphene and Other 2-D Nanomaterials 3The Global Market for Carbon Nanotubes, Graphene and Other 2-D Nanomaterials 4The Americas Inorganic Refrigerants Market is estimated to grow to $71.6 million by 2018 - New Report by MicroMarket Monitor 2The Americas Inorganic Refrigerants Market is estimated to grow to $71.6 million by 2018 - New Report by MicroMarket Monitor 3myPROpad™ Topic of Panel Discussion at the Yale Food Systems Symposium 2myPROpad™ Topic of Panel Discussion at the Yale Food Systems Symposium 3
... international scientific ... ... of antibody fragment therapeutics, today announced that it has,achieved high concentrations ... delivery via eye drops. These data were confirmed in,several independent preclinical ...
... from sunlight falling on only 9 percent of ... United States electricity needs if the energy could ... current-generation solar cell technologies are too expensive and ... of Northwestern University researchers has developed a new ...
... Monday, February 25, 2008 at ... ... Biopharmaceuticals,Inc. (Nasdaq: KERX ), a biopharmaceutical company focused on the,acquisition, ... of life-threatening,diseases, including diabetes and cancer (the "Company"), today announced,its results ...
Cached Biology Technology:ESBATech's Antibody Fragments Demonstrate Penetration into the Eye with Topical Delivery via Eye Drops 2ESBATech's Antibody Fragments Demonstrate Penetration into the Eye with Topical Delivery via Eye Drops 3Special coating greatly improves solar cell performance 2Keryx Biopharmaceuticals, Inc. Announces Fourth Quarter and Year-End 2007 Financial Results 2Keryx Biopharmaceuticals, Inc. Announces Fourth Quarter and Year-End 2007 Financial Results 3Keryx Biopharmaceuticals, Inc. Announces Fourth Quarter and Year-End 2007 Financial Results 4Keryx Biopharmaceuticals, Inc. Announces Fourth Quarter and Year-End 2007 Financial Results 5Keryx Biopharmaceuticals, Inc. Announces Fourth Quarter and Year-End 2007 Financial Results 6
(Date:10/22/2014)... Northwestern Medicine® scientists helps explain how bipolar disorder affects ... drug therapies to treat the mental illness. , ... same method recognized with the 2014 Nobel Prize ... tissue from mice with bipolar-like behaviors. In the synapses ... "nanodomain" structures with concentrated levels of ANK3 -- the ...
(Date:10/18/2014)... 2014 Psychological stress and stress-related psychiatric disorders are ... but the molecular mechanisms underlying this relation ... to the development of targeted preventive strategies ... devastating diseases. This work is presented at ... Berlin., Now an international group of researchers ...
(Date:10/17/2014)... University of Copenhagen have shown for the first time ... Cystic fibrosis patients, giving them the opportunity to get ... infections. , The study also discovered the bacterial growth ... was halted or slowed down by the immune cells. ... oxygen and helped "suffocate" the bacteria, forcing the bacteria ...
Breaking Biology News(10 mins):Bipolar disorder discovery at the nano level 2Researchers find why depression and aging linked to increased disease risk 2Scientists opens black box on bacterial growth in cystic fibrosis lung infection 2
... a corporation has a public relations crisis, the news media ... to new research in the Journal of Consumer Research the ... and the situation. "A company can control what face ... the face shape of this person is not a trivial ...
... better at making product choices, according to a new ... who understand their emotional ability can make higher quality ... explain the authors, Blair Kidwell, David M. Hardesty, and ... know a lot about nutrition and know what foods ...
... PROVIDENCE, R.I. [Brown University] Imagine being paralyzed, unable to ... to five million Americans suffer from this debilitating situation. Or ... millions of Americans are affected by these infirmities. Now ... your hands or arms enough to tap out an e-mail ...
Cached Biology News:Brown to host conference on advances in neurotechnology 2Brown to host conference on advances in neurotechnology 3
... The T2-04 is an ultra-compact pump available ... (T2-04 TH) and ideal for use in portable ... 7 slpm, this pump works well in environments ... weight, and compact size are critical., Offers ...
XA7 B6...
Curcumin is an extract of turmeric root with antioxidant, anti-tumor promoter, and anti-inflammatory properties. Curcumin inhibits the induction of NOS in macrophages....
... The MEGAscript RNAi Kit ... of large mass amounts of ... in non-mammalian systems. The MEGAscript ... Ambions patented high-yield transcription technol-ogy ...
Biology Products: